A Pilot Study of Whole-Brain Low-Intensity Pulsed Ultrasound Therapy for Early Stage of Alzheimer’s Disease (LIPUS-AD): A Randomized, Double-Blind, Placebo-Controlled Trial
Clinical endpoint
Extracorporeal shockwave therapy
DOI:
10.1620/tjem.2022.j078
Publication Date:
2022-09-14T22:10:12Z
AUTHORS (13)
ABSTRACT
The prevalence of Alzheimer's disease (AD) has been rapidly increasing worldwide. We have developed a novel angiogenic therapy with low-intensity pulsed ultrasound (LIPUS), which is effective and safe in animal models AD vascular dementia. performed two trials LIPUS for (mild cognitive impairment due to mild AD); roll-in open trial safety, randomized, double-blind, placebo-controlled (RCT) efficacy safety. was whole brain through the bilateral temporal bones one hour 3 times week as session under special conditions (1.3 MPa, 32 cycles, 5% duty cycle) we identified. trial, 6 sessions RCT 3-month intervals 1.5 years. primary endpoint ADAS-J cog scores. terminated prematurely COVID-19 pandemic. In (N = 5), no adverse effects were noted. 22), worsening scores tended be suppressed group compared placebo at 72 (P 0.257). When responders defined those 72, 50% (5/10) 0% (0/5) groups, respectively 0.053). No These results suggest that tends suppress although next pivotal large number subjects warranted.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (30)
CITATIONS (27)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....